Publications by authors named "Pedro Sanchez Maurino"
One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study.
Manuel Cobo Dols Carmen Beato Zambrano Luis Cabezón-Gutiérrez Rodolfo Chicas-Sett María Isabel Blancas López-Barajas
BMJ Support Palliat Care
December 2023
Objectives: Naloxegol is a peripherally acting µ-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patients with cancer in a real-world study.
Methods: This one-year prospective study included patients older than 18 years, with active oncological disease who were under treatment with opioids for pain control and Karnofsky≥50 and OIC with inadequate response to treatment with laxative (s).
Article Synopsis
- Opioid-induced constipation (OIC) affects up to 63% of cancer patients, prompting a study to evaluate the quality of life and effectiveness of naloxegol for those with OIC.
- An observational study involved 126 cancer patients who showed inadequate laxative response and were treated with naloxegol, using specific questionnaires to measure outcomes over three months.
- Results showed significant improvements in quality of life, increased bowel movements, and pain management after 15 days of treatment, with a good safety profile and only a small percentage experiencing mild to moderate gastrointestinal side effects.